Management Strategies for POSEIDON Groups 3 and 4
| Autor: | Thor Haahr, Carlos Dosouto, Carlo Alviggi, Sandro C. Esteves, Peter Humaidan |
|---|---|
| Přispěvatelé: | Haahr, T., Dosouto, C., Alviggi, C., Esteves, S. C., Humaidan, P. |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Pediatrics medicine.medical_specialty Poor prognosis medicine.medical_treatment Endocrinology Diabetes and Metabolism Population 030209 endocrinology & metabolism controlled ovarian stimulation lcsh:Diseases of the endocrine glands. Clinical endocrinology 03 medical and health sciences 0302 clinical medicine poor ovarian response ART calculator medicine education education.field_of_study Pregnancy Assisted reproductive technology lcsh:RC648-665 business.industry blastocyst medicine.disease POSEIDON criteria Bologna criteria 030104 developmental biology pregnancy business Poor ovarian reserve |
| Zdroj: | Frontiers in Endocrinology, Vol 10 (2019) Haahr, T, Dosouto, C, Alviggi, C, Esteves, S C & Humaidan, P 2019, ' Management Strategies for POSEIDON Groups 3 and 4 ', Frontiers in Endocrinology, vol. 10, 614, pp. 614 . https://doi.org/10.3389/fendo.2019.00614 |
| ISSN: | 1664-2392 |
| DOI: | 10.3389/fendo.2019.00614/full |
| Popis: | In the POSEIDON classification, patients belonging to groups 3 and 4 share the same common feature of a poor ovarian reserve which independently of age renders them at high risk of a poor reproductive outcome. Overall, POSEIDON groups 1-4 constitute approximately 47% of patients attending assisted reproductive technology (ART) treatment. With the increasing delay in childbearing, POSEIDON group 4 seems to increase in numbers now in some centers constituting more than 50% of the total POSEIDON population, whereas group 3 patients constitute approximately 10%. Both POSEIDON groups 3 and 4 patients require special attention as regards pre-treatment strategy, ovarian stimulation, adjuvant treatment, and ovulation trigger strategy in order to optimize the probability of having at least one euploid blastocyst for transfer. Although more evidence is needed, recent advances seem to have increased the reproductive outcomes in the poor prognosis patient. The key to success is individualization in all steps of ART treatment. Herein, we review the recent evidence for the management of POSEIDON groups 3 and 4. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|